Here are four things to know.
1. The company reported $5.944 billion in worldwide sales for the third quarter, an 18.4 percent year-over-year increase.
2. AbbVie’s Viekira global sales for the quarter were $469 million. The HCV drug is now approved in 61 countries.
3. The company’s net interest expense for the quarter was $197 million.
4. AbbVie’s diluted earnings per share for the third quarter were $1.31, up approximately 27 percent.
More articles on gastroenterology:
Lovelace Medical Group adds Dr. Julie Farrer: 3 things to know
Global endoscopy market to reach $9.7B by 2021: 5 key trends
The biggest challenges for GI in 2016: 3 gastroenterologists weigh in
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
